Takeover chatter of AVEO for $19.41 per share
Jazz Pharmaceuticals is said to be considering a full and special tender offer according to unconfirmed chatter circulating on Tuesday for the acquisition of AVEO Pharmaceuticals pursuant to which Jazz will acquire AVEO for $19.41 per share in cash via a tender offer. The transaction values AVEO at approximately $2.3 billion and is expected to close in Q4 of 2017.
A Jazz representative declined comment on the report.
UKJournalists, its employees, partners, and any other representatives will not, either directly or indirectly, be held liable, accountable, or responsible, in any capacity, to you or to any other person for any (i) errors, inaccuracies, or omissions from the Services including, but not limited to, quotes, rumors, chatter, financial data, and reports; (ii) interruptions, delays, or errors in delivery or transmission of the Services, (iii) damages or losses arising there from or occasioned because of, or by any reason of nonperformance. Some of UKJournalists content may include mentions of rumors, chatter, or unconfirmed information. Readers should beware that while unconfirmed information may be correlated with increased volatility in securities, price movements based on unofficial information may change quickly based on increased speculation, clarification, or release of official news.